COX-2 (SP21)

Skip to Content

Skip over Generic Navigation

  • Select your country:
DIAGNOSTICS F. Hoffmann-La Roche Ltd

COX-2 (SP21)

COX-2 (SP21), colon carcinoma, 130x
Catalog Number:760-4254
Ordering Code:05269148001
Quantity:50 tests
Controls:Colon Adenocarcinoma
Clone Name:SP21
Regulatory Status:IVD

Cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin H2 in the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. COX-2 inhibition by nonsteroidal antiinflamatory agents has been shown to decrease angiogenesis, and tumor growth, and promote apoptosis. COX-2 overexpression has been associated with increased microvascular density, and VEGF protein expression in head and neck squamous cell carcinoma and is a poor prognostic indicator in this entity as well. COX-2 overexpression has also been suggested as a poor prognostic indicator in carcinomas of the colon, breast, pancreas, and adenocarcinoma of the lung.